Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life.
OBJECTIVE
Patients with atrial fibrillation (AF) consider the related symptoms disruptive to their quality of life (QoL). This study aimed to evaluate the impact of the control of symptomatic paroxysmal AF (PAF) on QoL.


RESULTS
Patients with symptomatic PAF were treated for 48 weeks with open-label flecainide acetate controlled release (Flec CR). Quality of life was assessed by SF-36 and Atrial Fibrillation Severity Scale scores at baseline, Week 12 (W12), W24, and W48. Of the 229 treated patients, 217 were analysed for QoL (123 with controlled and 94 with uncontrolled symptomatic PAF at inclusion). The controlled group had a similar or better QoL (SF-36) at baseline compared with a reference population (significantly better for: physical functioning, bodily pain, and physical component). The uncontrolled group had an inferior QoL (significantly worse for: role physical, general health, vitality, role emotional, social functioning, mental health, and mental component). When treated with Flec CR, the controlled group baseline QoL scores were maintained and the uncontrolled group scores were improved to a level comparable to the controlled group scores. Safety findings reflect the known clinical safety profile of flecainide acetate.


CONCLUSIONS
In this study, patients with uncontrolled symptomatic PAF at baseline had an inferior QoL to those with controlled symptomatic PAF. Following treatment with controlled-release flecainide acetate, their QoL improved to a level comparable to controlled patients.
Hôpital Cardiologique, Service de Cardiologie, CHRU Lille, Lille, France.
Laurence
L
Guédon-Moreau
Alessandro
A
Capucci
Isabelle
I
Denjoy
Caroline Claire
CC
Morgan
Antoine
A
Périer
Alain
A
Leplège
Salem
S
Kacet
D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D017281:Cost of Illness; D005260:Female; D005424:Flecainide / Q000627:therapeutic use*; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life / Q000523:psychology*; D012650:Self Disclosure; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D005424:Flecainide